Compare Stocks: FATE, AVTX, JANX, and KURA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$19.59	$18.98	$8.65 ▼ $24.27	$1.05B	0.8	715,537 shs	738,276 shs
FATE Fate Therapeutics	$2.43	$2.61	$0.93 ▼ $3.23	$291.16M	2.52	2.09 million shs	709,819 shs
JANX Janux Therapeutics	$18.03	$16.12	$12.12 ▼ $35.34	$1.10B	2.5	705,286 shs	637,808 shs
KURA Kura Oncology	$12.66	$10.86	$7.36 ▼ $13.90	$1.13B	0.38	2.23 million shs	1.81 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	0.00%	-1.21%	+7.34%	+24.38%	+110.87%
FATE Fate Therapeutics	0.00%	+4.29%	-0.82%	-11.31%	+133.65%
JANX Janux Therapeutics	0.00%	+3.68%	+18.85%	+25.12%	-20.64%
KURA Kura Oncology	0.00%	+6.48%	+40.51%	+40.20%	+60.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$19.59	$18.98	$8.65 ▼ $24.27	$1.05B	0.8	715,537 shs	738,276 shs
FATE Fate Therapeutics	$2.43	$2.61	$0.93 ▼ $3.23	$291.16M	2.52	2.09 million shs	709,819 shs
JANX Janux Therapeutics	$18.03	$16.12	$12.12 ▼ $35.34	$1.10B	2.5	705,286 shs	637,808 shs
KURA Kura Oncology	$12.66	$10.86	$7.36 ▼ $13.90	$1.13B	0.38	2.23 million shs	1.81 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	0.00%	-1.21%	+7.34%	+24.38%	+110.87%
FATE Fate Therapeutics	0.00%	+4.29%	-0.82%	-11.31%	+133.65%
JANX Janux Therapeutics	0.00%	+3.68%	+18.85%	+25.12%	-20.64%
KURA Kura Oncology	0.00%	+6.48%	+40.51%	+40.20%	+60.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTX Avalo Therapeutics	2.86	Moderate Buy	$45.10	130.22% Upside
FATE Fate Therapeutics	2.38	Hold	$5.90	142.80% Upside
JANX Janux Therapeutics	2.67	Moderate Buy	$36.46	102.23% Upside
KURA Kura Oncology	2.69	Moderate Buy	$25.40	100.63% Upside

Current Analyst Ratings Breakdown

Latest FATE, AVTX, JANX, and KURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	JANX Janux Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$23.00
8/24/2026	KURA Kura Oncology	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00
8/24/2026	KURA Kura Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00
8/24/2026	KURA Kura Oncology	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/24/2026	JANX Janux Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/24/2026	KURA Kura Oncology	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$24.00
8/14/2026	FATE Fate Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$6.00 ➝ $8.00
8/14/2026	FATE Fate Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$2.50 ➝ $3.50
8/14/2026	FATE Fate Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$7.00
8/13/2026	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$36.00 ➝ $38.00
8/11/2026	AVTX Avalo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTX Avalo Therapeutics	$59K	17,806.98	N/A	N/A	$4.49 per share	4.36
FATE Fate Therapeutics	$6.65M	43.78	N/A	N/A	$1.80 per share	1.35
JANX Janux Therapeutics	$24M	45.93	N/A	N/A	$15.91 per share	1.13
KURA Kura Oncology	$67.48M	16.69	N/A	N/A	$2.00 per share	6.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTX Avalo Therapeutics	-$78.26M	-$4.37	N/A	N/A	N/A	N/A	-58.03%	-48.22%	11/5/2026 (Estimated)
FATE Fate Therapeutics	-$136.32M	-$1.05	N/A	N/A	N/A	-1,941.09%	-65.08%	-41.73%	10/29/2026 (Estimated)
JANX Janux Therapeutics	-$113.62M	-$1.64	N/A	N/A	N/A	N/A	-11.89%	-11.13%	11/5/2026 (Estimated)
KURA Kura Oncology	-$278.67M	-$3.37	N/A	N/A	N/A	-384.30%	-207.18%	-45.17%	11/3/2026 (Estimated)

Latest FATE, AVTX, JANX, and KURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	FATE Fate Therapeutics	-$0.2536	-$0.25	+$0.0036	-$0.25	$1.94 million	$2.08 million
8/12/2026	Q2 2026	KURA Kura Oncology	-$0.8773	-$0.77	+$0.1073	-$0.77	$20.16 million	$20.87 million
8/6/2026	Q2 2026	AVTX Avalo Therapeutics	-$0.5827	-$0.83	-$0.2473	-$0.83	N/A	N/A
8/6/2026	Q2 2026	JANX Janux Therapeutics	-$0.2513	-$0.35	-$0.0987	-$0.35	$19.08 million	$10.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTX Avalo Therapeutics	N/A	19.31	19.31
FATE Fate Therapeutics	N/A	4.85	4.85
JANX Janux Therapeutics	N/A	16.35	16.35
KURA Kura Oncology	0.12	4.73	4.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTX Avalo Therapeutics	87.06%
FATE Fate Therapeutics	97.54%
JANX Janux Therapeutics	75.39%
KURA Kura Oncology	N/A

Insider Ownership

Company	Insider Ownership
AVTX Avalo Therapeutics	4.46%
FATE Fate Therapeutics	4.74%
JANX Janux Therapeutics	7.90%
KURA Kura Oncology	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTX Avalo Therapeutics	40	53.63 million	51.24 million	Not Optionable
FATE Fate Therapeutics	550	119.82 million	114.14 million	Optionable
JANX Janux Therapeutics	30	61.14 million	56.31 million	Optionable
KURA Kura Oncology	130	88.96 million	82.20 million	Optionable

FATE, AVTX, JANX, and KURA Headlines

Recent News About These Companies

BlackRock Inc. Takes $115.29 Million Position in Kura Oncology, Inc. $KURA

August 30 at 3:29 AM | marketbeat.com

Cancer Biotech Kura Oncology Rallies to New High After CEO’s Stock Purchase

August 27, 2026 | msn.com

Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves

August 27, 2026 | zacks.com

Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Kura Oncology, Inc. $KURA

August 27, 2026 | marketbeat.com

Kura Oncology (NASDAQ:KURA) Sets New 1-Year High After Insider Buying Activity

August 27, 2026 | americanbankingnews.com

Kura Oncology: 'Strong Buy': Ziftomenib AML Expansions With Different Regimens Could Boost KOMZIFTI's Prospects

August 26, 2026 | seekingalpha.com

Kura Oncology shares jump after CEO buys $1.24 million of stock

August 26, 2026 | msn.com

kura oncology inc. - KURA

August 26, 2026 | foxbusiness.com

Kura's CEO Just Wrote Two Real Checks. The Stock Noticed.

August 26, 2026 | moneymorning.comM

Citizens Jmp Reiterates "Market Outperform" Rating for Kura Oncology (NASDAQ:KURA)

August 26, 2026 | americanbankingnews.com

Stocks making the biggest moves midday: Dick's Sporting Goods, Marvell, AMD, Kura Oncology & more

August 25, 2026 | cnbc.com

Kura Oncology Earnings Call Highlights COMZIFTI Momentum

August 25, 2026 | theglobeandmail.com

KURA stock hits fresh 52-week high as CEO buys more shares — retail wonders if Wilson is following Moderna CEO’s playbook

August 25, 2026 | msn.com

The $1.24 billion reason why Kura Oncology stock is up today

August 25, 2026 | msn.com

Kura Oncology CEO Buys 100,000 Shares for $1.2 Million. Does This Large Buy Bode Well for Shares in 2026?

August 25, 2026 | fool.com

Kura Oncology (NASDAQ:KURA) Hits New 1-Year High on Insider Buying Activity

August 25, 2026 | marketbeat.com

Ieq Capital LLC Invests $3.82 Million in Kura Oncology, Inc. $KURA

August 25, 2026 | marketbeat.com

Kura Oncology (NASDAQ:KURA) Insider Brian Powl Sells 4,345 Shares

August 25, 2026 | insidertrades.com

Kura Oncology (NASDAQ:KURA) Insider Sells $51,662.05 in Stock

August 24, 2026 | marketbeat.com

Kura Oncology (NASDAQ:KURA) CEO Purchases 100,000 Shares

August 24, 2026 | marketbeat.com

Kura Oncology (NASDAQ:KURA) Shares Up 5% - Should You Buy?

August 24, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE, AVTX, JANX, and KURA Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

$19.59 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Fate Therapeutics NASDAQ:FATE

$2.43 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Janux Therapeutics NASDAQ:JANX

$18.03 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Kura Oncology NASDAQ:KURA

$12.66 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FATE, AVTX, JANX, and KURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FATE, AVTX, JANX, and KURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FATE, AVTX, JANX, and KURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE, AVTX, JANX, and KURA Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

Fate Therapeutics NASDAQ:FATE

Janux Therapeutics NASDAQ:JANX

Kura Oncology NASDAQ:KURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FATE, AVTX, JANX, and KURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FATE, AVTX, JANX, and KURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FATE, AVTX, JANX, and KURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE, AVTX, JANX, and KURA Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

Fate Therapeutics NASDAQ:FATE

Janux Therapeutics NASDAQ:JANX

Kura Oncology NASDAQ:KURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools